Filing Analysis
Amarin Corporation plc issued an 8-K to furnish its quarterly financial results for the three and nine months ended September 30, 2025. The filing serves as a formal announcement of the company's recent operational performance.
📋 Key Facts
- Report date: October 29, 2025
- Reporting period: Three and nine months ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
- Information provided under Item 2.02 is furnished, not filed, for purposes of Section 18 of the Exchange Act.
Amarin Corporation plc announced the promotion of David Keenan, Ph.D., to the position of Executive Vice President and Chief Operating Officer (COO), effective October 17, 2025.
📋 Key Facts
- David Keenan, Ph.D., appointed as EVP and COO effective October 17, 2025.
- Keenan previously served as EVP, Technical Operations and President of Europe.
- No change in compensation was reported as a result of this appointment.
- Keenan has been with the company since May 2022.
Amarin Corporation plc issued an 8-K to furnish its quarterly financial results for the three and six months ended June 30, 2025. The filing serves as a formal announcement of the company's recent operational performance.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2025, and 2024.
- Filing date: July 30, 2025.
- The report includes results of operations and financial condition via a press release (Exhibit 99.1).
- Signed by Aaron Berg, President and CEO.
This 8-K/A amendment supplements a previous filing to disclose specific compensation arrangements for newly appointed non-employee director Michael Torok. The disclosure highlights an inability to issue equity grants due to shareholders' failure to renew pre-emption disapplication.
🚩 Red Flags
- Shareholders' failure to renew pre-emption disapplication limits the Board's ability to issue equity grants.
- The company is forced to use cash ($175,000) for director compensation due to regulatory/shareholder constraints, which may impact liquidity.
📋 Key Facts
- Michael Torok was appointed as a new non-employee director effective April 4, 2025.
- Mr. Torok was appointed to the Remuneration Committee effective July 1, 2025.
- Due to shareholder failure to renew pre-emption disapplication, the company cannot issue equity grants for certain compensation components.
- Mr. Torok will receive a $175,000 restricted cash award in lieu of his 2025 annual equity award, payable at the 2026 Annual Meeting subject to continued service.
- A potential initial equity award (75% options / 25% RSUs) with a fair value of $262,500 is contingent upon a waiver of pre-emptive rights being approved at the 2026 Annual Meeting.
Amarin Corp announced a major 15-year exclusive license agreement with Recordati for VAZKEPA in 59 European countries, involving an upfront payment of $25M and up to $150M in milestones. Simultaneously, the company is undergoing a global restructuring to exit its own European commercial operations, expecting $70M in annual cost savings.
🚩 Red Flags
- Multiple material items in a single filing (License Agreement + Restructuring).
- Significant restructuring charges ($30M-$37M) being recognized in Q2 2025.
- Strategic pivot/exit from direct European commercialization suggests previous operational inefficiencies or capital constraints.
📋 Key Facts
- Entered into exclusive long-term license/supply agreement with Recordati Industria Chimica e Farmaceutica S.p.A. on June 20, 2025.
- Agreement covers development and commercialization of VAZKEPA in 59 countries (Europe territory).
- Upfront payment: $25 million.
- Potential milestone payments: up to $150 million.
- Royalty structure based on net sales by Recordati/sublicensees.
- Initial term of agreement is 15 years with automatic renewal options.
- Global restructuring announced to reduce commercialization expenses in Europe.
- Expected annual operating cost savings: ~$70 million.
- Estimated restructuring charges: $30 million to $37 million, mostly cash-based termination benefits.
- Restructuring expected to be substantially complete by June 30, 2026.
Amarin Corporation plc held its Annual General Meeting on May 13, 2025. While most director re-elections and auditor appointments were approved, shareholders rejected a key proposal to waive statutory pre-emption rights for certain allotments.
🚩 Red Flags
- Shareholder rejection of pre-emption rights waiver increases administrative burden and cost for future capital raises.
- Shift from equity to cash compensation for directors will negatively impact the Company's total cash position.
📋 Key Facts
- Annual Meeting held on May 13, 2025; quorum was approximately 60% of shares entitled to vote.
- Proposal 12 (waiving statutory pre-emption rights for ~10% of issued share capital) failed to receive requisite shareholder approval despite ISS and Glass Lewis recommendations.
- The Board must now obtain express opt-outs for future stock issuances, which is described as time-consuming and expensive.
- Due to the rejection, the Board will likely shift non-employee director compensation from equity to supplemental cash compensation.
- Ernst & Young LLP was re-appointed as the U.S. independent registered public accounting firm.
Amarin Corporation plc has filed an 8-K to furnish its quarterly press release announcing financial results for the three months ended March 31, 2025.
📋 Key Facts
- Report date: May 7, 2025
- Reporting period: Three months ended March 31, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Amarin Corporation plc has regained compliance with the Nasdaq minimum bid price requirement. Following a reverse stock split (ADS ratio adjustment) on April 11, 2025, the company's American Depositary Shares are now in compliance with all applicable listing standards.
🚩 Red Flags
- Previous non-compliance with minimum bid price requirement.
- Execution of a reverse stock split (ratio adjustment) to avoid delisting.
📋 Key Facts
- On April 29, 2025, Nasdaq confirmed the Company regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)).
- The company previously fell below the $1.00 minimum bid price for 30 consecutive business days.
- On April 11, 2025, the Company executed a reverse stock split by adjusting the ADS ratio from 1:1 to 1:20 (one ADS now represents twenty Ordinary Shares).
- The company remains listed on the Nasdaq Capital Market.
Amarin Corp PLC is implementing a 1-for-20 reverse stock split of its American Depositary Shares (ADSs) effective April 11, 2025. This adjustment changes the ratio from 1 ADS per Ordinary Share to 1 ADS per 20 Ordinary Shares.
🚩 Red Flags
- Reverse stock split (typically used to combat low share prices or meet exchange listing requirements)
- Significant dilution of unit count per shareholder
📋 Key Facts
- Effective Date: April 11, 2025
- Ratio Change: 1 ADS will represent 20 Ordinary Shares (previously 1:1)
- Impact: One-for-twenty reverse split of issued and outstanding ADSs
- Ordinary Shares: The ratio change has no effect on the underlying Ordinary Shares themselves, only the ADS representation.
Amarin Corporation plc announced the appointment of Michael Torok to its Board of Directors, effective April 4, 2025. Mr. Torok will serve until the company's 2025 annual general meeting, where he will be a nominee for election.
📋 Key Facts
- Michael Torok appointed to the Board of Directors on April 4, 2025.
- Term expires at the 2025 annual general meeting of shareholders unless elected by shareholders.
- Mr. Torok has not been assigned to any specific board committees.
- Compensation will follow the Company’s non-employee director compensation policy as disclosed in the March 4, 2024 Proxy Statement.
Amarin Corporation plc announced that Mark DiPaolo will not stand for re-election at the upcoming 2025 Annual Meeting of Shareholders. He is expected to step down from the Board of Directors in May 2025.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Notification date: March 25, 2025
- Departure timing: Conclusion of the 2025 Annual Meeting of Shareholders (expected May 2025)
- Reason for departure: Decision not to stand for re-election; no disagreement with Company operations, policies, or practices reported.
Amarin Corporation plc announced a 1-for-20 reverse stock split of its American Depositary Shares (ADSs) effective on or about April 11, 2025. This action changes the ratio from 1 ADS per Ordinary Share to 1 ADS per 20 Ordinary Shares.
🚩 Red Flags
- Reverse stock split (1-for-20) is a significant red flag often used to prevent delisting or to artificially inflate share price.
- The filing includes the announcement of financial results (Item 2.02), which may contain liquidity concerns given the simultaneous reverse split.
📋 Key Facts
- The ADS Ratio Change will result in a one-for-twenty reverse split of issued and outstanding ADSs.
- Effective date is expected to be on or about April 11, 2025.
- The ratio change affects only the ADSs; it has no effect on the underlying Ordinary Shares.
- The company simultaneously released its financial results for the three and twelve months ended December 31, 2024, and 2023.
Amarin Corporation plc announced the appointment of Peter Fishman as Chief Financial Officer (CFO), effective December 13, 2024. Mr. Fishman transitions from his role as Global Controller and Principal Financial & Accounting Officer to the CFO position.
📋 Key Facts
- Peter Fishman appointed as CFO effective December 13, 2024.
- Fishman previously served as Principal Financial & Accounting Officer since October 2024 and VP & Global Controller since October 2022.
- New compensation includes an annual base salary of $400,000 and a discretionary bonus potential of up to 40% of base salary.
- Fishman is a CPA with approximately 20 years of experience in finance, including roles at Ernst & Young and Toys R Us.
Amarin Corporation plc received a notice from Nasdaq granting an 180-day extension to regain compliance with the minimum bid price requirement. The company's ADS will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective November 26, 2024.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)).
- Downgrade in market tier from Nasdaq Global Market to Nasdaq Capital Market.
- Explicit mention of a potential reverse stock split to avoid delisting.
📋 Key Facts
- Nasdaq granted a 180-day extension until May 19, 2025, to regain compliance with the $1.00 minimum bid price requirement.
- ADS will be transferred from Nasdaq Global Market to Nasdaq Capital Market on November 26, 2024.
- Compliance can be achieved if the ADS closing bid price is at least $1.00 for 10 consecutive business days.
- The company explicitly mentions a reverse stock split as a potential option to regain compliance.
Amarin Corporation plc filed an 8-K to furnish its quarterly press release announcing financial results for the three and nine months ended September 30, 2024. The filing is a standard disclosure of results of operations and does not contain substantive new material agreements or structural changes.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2024, and 2023.
- Filing date: October 30, 2024.
- The report is filed under Item 2.02 (Results of Operations and Financial Condition).
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Amarin Corporation plc announced the voluntary resignation of its CFO, Tom Reilly, effective October 23, 2024. The company has appointed Peter Fishman as interim principal financial and accounting officer.
🚩 Red Flags
- Departure of a key C-suite executive (CFO) during an active period for the company.
📋 Key Facts
- Tom Reilly is resigning from his roles as EVP, CFO, and Head of Global HR & Finance on October 23, 2024.
- Resignation was voluntary to pursue another opportunity.
- The company stated the resignation is not due to any disagreement regarding financial statements, operations, or accounting practices.
- Peter Fishman (VP, Global Controller) will serve as interim CFO and principal accounting officer.
- Fishman has been with the company since 2019 and served as Global Controller since October 2022.
Amarin Corporation plc issued an 8-K to furnish its quarterly financial results for the three and six months ended June 30, 2024. The filing serves as a formal announcement of the company's recent operational performance.
📋 Key Facts
- Report date: July 31, 2024
- Reporting period: Three and six months ended June 30, 2024, and 2023
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
Amarin Corporation plc has disclosed the specific terms of the employment agreement for newly appointed President and CEO Aaron Berg, effective June 4, 2024. The filing details his compensation structure, including a $700,000 base salary and performance-based stock options tied to share price hurdles.
🚩 Red Flags
- Significant severance obligations: potential payout of up to 3.3x base salary in the event of termination during a Change in Control period.
📋 Key Facts
- Aaron Berg appointed as President and CEO effective June 4, 2024.
- Annual base salary set at $700,000.
- Performance-based stock option award of 5,000,000 shares based on share price hurdles ranging from $1.25 to $10.00.
- Option exercise price expected to be the closing price on August 1, 2024.
- CEO agreed to a personal cash investment of $100,000 in Company shares.
- Severance terms include 18 months of base salary (plus lump sum) for termination without cause outside a Change in Control period.
Amarin Corp PLC announced the immediate voluntary resignation of CEO Patrick Holt and the appointment of Aaron Berg as his successor. Simultaneously, the company disclosed a significant negative regulatory/reimbursement development regarding its product VASCEPA.
🚩 Red Flags
- Immediate departure of the CEO (even if voluntary) creates leadership transition risk.
- Significant loss of market access: A major PBM is removing coverage for VASCEPA, impacting 25% of total U.S. prescription volume.
- The combination of a leadership change and a material revenue headwind (PBM decision) increases volatility risk.
📋 Key Facts
- CEO Patrick Holt resigned voluntarily effective June 3, 2024; no disagreement with the company reported.
- Patrick Holt will provide consulting services until July 3, 2024 at his current base salary rate.
- Aaron Berg (formerly EVP, President U.S.) appointed as CEO and Board member effective June 4, 2024.
- A large national Pharmacy Benefit Manager (PBM) will transition VASCEPA to 'not covered' on its Commercial national formularies effective July 1, 2024.
- The PBM decision affects approximately 25% of aggregate U.S. VASCEPA prescription volume.
Amarin Corporation plc received a deficiency letter from Nasdaq because its American Depositary Shares (ADSs) have traded below the $1.00 minimum bid price for 30 consecutive business days. The company has until November 20, 2024, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice (Nasdaq deficiency letter)
- Stock price has been below $1.00 for 30 consecutive business days
- Risk of delisting from The Nasdaq Global Market
📋 Key Facts
- Received deficiency letter from Nasdaq Listing Qualifications Department on May 24, 2024.
- Violation of Nasdaq Listing Rule 5450(a)(1) regarding the $1.00 minimum bid price requirement.
- The company has a 180-day grace period to regain compliance, expiring November 20, 2024.
- Compliance can be achieved if the ADS closes at $1.00 or more for 10 consecutive business days.
- A second 180-day period may be available if the company transfers listing to Nasdaq Capital Market.
Amarin Corporation plc filed an 8-K to furnish its quarterly press release announcing financial results for the three months ended March 31, 2024. This is a routine earnings announcement filing.
📋 Key Facts
- Report date: May 1, 2024
- Reporting period: Three months ended March 31, 2024
- The filing contains results of operations and financial condition as per Item 2.02.
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Amarin Corporation plc held its Annual General Meeting (AGM) on April 18, 2024, where shareholders approved several key items including the re-election of directors and an amendment to the 2020 Stock Incentive Plan. The filing also details voting results for auditor appointment and a share repurchase agreement.
🚩 Red Flags
- Significant 'Broker Non-Votes' (approx. 111 million shares) across multiple items, indicating a high level of non-participation or inability of brokers to vote on certain matters for their clients.
📋 Key Facts
- Shareholders approved Amendment No. 3 to the 2020 Stock Incentive Plan, increasing the share reserve by 10,000,000 ordinary shares/ADSs.
- Ernst & Young LLP was re-appointed as the Company’s U.S. independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Shareholders approved terms of a share repurchase agreement dated January 9, 2024, with Cantor Fitzgerald & Co.
- The company's Articles of Association were amended to eliminate the classified board structure, requiring all directors to seek annual re-election.
- Approximately 61% of ordinary shares entitled to vote were present or represented at the meeting.
Amarin Corporation plc issued an 8-K to provide a press release regarding updates to its VAZKEPA (Icosapent Ethyl) intellectual property portfolio in Europe.
📋 Key Facts
- The filing is dated April 3, 2024.
- The company provided an update specifically concerning the VAZKEPA (Icosapent Ethyl) IP portfolio in Europe.
- The primary content of the update was furnished via a press release (Exhibit 99.1).
Amarin Corporation plc filed an 8-K to furnish its quarterly earnings press release for the three and twelve months ended December 31, 2023. The filing is a standard regulatory requirement following the announcement of financial results.
📋 Key Facts
- Report date: February 29, 2024
- Reporting period: Three and twelve months ended December 31, 2023
- The company issued a press release (Exhibit 99.1) regarding results of operations and financial condition.
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Amarin Corporation plc has regained compliance with the NASDAQ minimum bid price requirement. The company successfully maintained a closing bid price of $1.00 or more for 10 consecutive trading days, ending on January 24, 2024.
🚩 Red Flags
- Previous non-compliance with minimum bid price requirements (minimum $1.00 requirement).
📋 Key Facts
- Received notice from Nasdaq on January 25, 2024, confirming compliance with NASDAQ Listing Rule 5450(a)(1).
- The company met the requirement of maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days.
- Compliance was officially achieved on January 24, 2024.
- The matter regarding the previous delisting notice from October 30, 2023, is now considered closed.
Amarin Corporation plc issued an 8-K to announce its preliminary 2023 revenue results, year-end cash position, and strategic priorities for 2024. The company also announced it will present these details at the J.P. Morgan Healthcare Conference.
📋 Key Facts
- Announced preliminary 2023 revenue results via press release (Exhibit 99.1).
- Disclosed year-end cash position and 2024 priorities.
- Scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024.
- Provided an investor deck (Exhibit 99.2) for use during the conference webcast.